A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
A phase 1/2 trial of Nivolumab, Docetaxel, PM8002 in cervical cancer and colorectal cancer, run by Bristol-Myers Squibb, now recruiting.
Overview
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT04895709 by Bristol-Myers Squibb, with 1109 participants planned, started 2021-05-27 and due to reach its primary completion in 2031-08-31. Interventions recorded: BMS-986340, BMS-936558-01, Docetaxel, Pumitamig. Conditions listed: Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer, Non-Small-Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and P
Shares PM8002, Bristol Myers Squibb, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell
Shares PM8002, Bristol Myers Squibb, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialSafety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Che
Shares PM8002, Docetaxel, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung
Shares PM8002, Bristol Myers Squibb, Small-cell lung cancer.
- TrialEffectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma
Shares Bristol Myers Squibb, Nivolumab, Melanoma.
- TrialA Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer
Shares Docetaxel, Bristol Myers Squibb, Nivolumab, Non-small-cell lung cancer.
- TrialA Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pu
Shares PM8002, Bristol Myers Squibb, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
Shares PM8002, Bristol Myers Squibb, Nivolumab.